ONCT רווח למניה בשנים עשר החודשים האחרונים Oncternal Corp

Oncternal Therapeutics (ONCT) is currently restructuring its R&D priorities, which has created a temporary lull in innovation. On GURU.Markets, the annual net income per share chart visualizes this period, where the value -11.70 represents the current figure. The company's revenues are based on leukemia treatment partnerships, while financial stability relies on the success of zilovertamab and available capital.

Selecting assets with a high margin of safety begins with an analysis of return on equity. Net income per share over 12 months measures the business's bottom-line earnings distributed across the total volume of issuance. For Oncternal Therapeutics (ONCT), this metric reflects the efficiency of antibody supply optimization and protection against logistical shocks. The trend in net income per share over 12 months reveals the impact of costs on margins. It is critical for investors to correlate this trend with the company's debt load.